196 related articles for article (PubMed ID: 36869126)
1. Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer.
Huang JQ; Duan LX; Liu QY; Li HF; Hu AP; Song JW; Lin C; Huang B; Yao D; Peng B; Sun Y; Wen Y; Yang L; Xu X; Gong LY
Oncogene; 2023 Apr; 42(15):1233-1246. PubMed ID: 36869126
[TBL] [Abstract][Full Text] [Related]
2. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
4. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
Huang HN; Hung PF; Chen YP; Lee CH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
[TBL] [Abstract][Full Text] [Related]
5. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
6. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.
Dai J; Qu T; Yin D; Cui Y; Zhang C; Zhang E; Guo R
Cell Death Dis; 2023 May; 14(5):312. PubMed ID: 37156816
[TBL] [Abstract][Full Text] [Related]
7. The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression.
Ren S; Zhu Y; Wang S; Zhang Q; Zhang N; Zou X; Wei C; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(1):81-90. PubMed ID: 36471952
[TBL] [Abstract][Full Text] [Related]
8. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
9. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
Kim MS; Kim SH; Yang SH; Kim MS
Cancer Res Treat; 2022 Apr; 54(2):445-457. PubMed ID: 34352998
[TBL] [Abstract][Full Text] [Related]
10. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
11. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.
Liu WJ; Wang L; Zhou FM; Liu SW; Wang W; Zhao EJ; Yao QJ; Li W; Zhao YQ; Shi Z; Qiu JG; Jiang BH
Drug Resist Updat; 2023 Sep; 70():100987. PubMed ID: 37392558
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
13. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
14. Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.
Hatat AS; Benoit-Pilven C; Pucciarelli A; de Fraipont F; Lamothe L; Perron P; Rey A; Levra MG; Toffart AC; Auboeuf D; Eymin B; Gazzeri S
Mol Oncol; 2022 Oct; 16(19):3490-3508. PubMed ID: 35593080
[TBL] [Abstract][Full Text] [Related]
15. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
[TBL] [Abstract][Full Text] [Related]
16. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
17. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
18. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
19. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
[TBL] [Abstract][Full Text] [Related]
20. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
Wen Q; Jiao X; Kuang F; Hou B; Zhu Y; Guo W; Sun G; Ba Y; Yu D; Wang D; Zhang F; Qiao HC; Wang S; Tang S; Qiao H
EBioMedicine; 2019 Feb; 40():198-209. PubMed ID: 30738830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
